ArticleJournal of robotic surgery2026
A multi‑criteria decision analysis comparing robot‑assisted, laparoscopic, and open radical cystectomy using large-scale Japanese nationwide databases.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to provide an integrated, probability-based comparison of robot-assisted radical cystectomy (RARC), laparoscopic radical cystectomy (LRC), and open radical cystectomy (ORC) in Japan by jointly evaluating clinical and economic outcomes using multi-criteria decision analysis (MCDA). Clinical and economic outcomes were extracted from large nationwide studies based on the National Clinical Database and the Diagnosis Procedure Combination database in Japan, including estimated blood loss, grade ≥ 3 complications, lymph node count, in-hospital fee, length of stay, and transfusion rates. Outcome uncertainty was propagated using parametric bootstrap resampling with 50,000 iterations, and criterion-specific values were normalized to a common 0-1 scale within each iteration. Six prespecified weighting scenarios (balanced, safety-focused, perioperative-focused, oncology-focused, cost-focused, and efficiency-focused) produced overall scores, rank probabilities, and pairwise net advantages. Sensitivity analyses were conducted to assess the robustness of the results. Across all weighting scenarios, both minimally invasive approaches outperformed ORC, with RARC consistently achieving the highest expected MCDA scores and rank probabilities. The advantage of RARC over LRC remained evident across scenarios, including cost-focused analyses, but was attenuated under safety-focused weighting. Sensitivity analyses did not materially alter the overall ranking patterns. Using MCDA to integrate heterogeneous clinical and economic outcomes from Japanese nationwide data, RARC most frequently emerged as the preferred surgical approach over LRC and ORC. This transparent and reproducible framework supports informed clinical decision-making and policy discussions regarding the role of RARC in Japan.
Indexed as
Identifiers
41663669What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.